MPM/Novartis Fund Deals with Radius
Executive Summary
In mid-September, the MPM Capital/Novartis investment fund closed a $10 million investment in Radius Health -- getting an option on Radius's Phase II osteoporosis candidate and the first evidence that its strategy of melding business development with VC can work. And that's why the outcome will be important to watch. If the Radius deal is followed by others, Big Pharma will try to copy the model. If the deal is seen as preventing Radius from getting a profitable exit for its investors, serving Novartis' needs at their expense, corporate VC will go back to the drawing board.
You may also be interested in...
Radius Raises $91 Million, Moves Toward Public Listing
Just two years ago Radius Health Inc. had a straightforward partnering strategy for its osteoporosis drug, BA058. Now that a key partner has opted not to exercise its option on the compound, Radius has instead raised a massive new round of funding that allows the company to keep full ownership of the compound. In addition, the crafting of a creative exit strategy alongside the financing paves a path to liquidity for its shareholders.
Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing
Five new investors back the owner of anabolic bone therapy BA058, while a reverse merger paves the way to the public markets.
Radius Takes $91MM To Support Osteoporosis Drug, Moves Toward Public Listing
Five new investors back the owner of anabolic bone therapy BA058, while a reverse merger paves the way to the public markets.